Commitments and Contingencies (Details) ₪ in Thousands, $ in Thousands |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 23, 2022
USD ($)
|
Oct. 31, 2020
USD ($)
|
Sep. 01, 2020
USD ($)
|
Dec. 31, 2017
USD ($)
|
Apr. 30, 2017
USD ($)
|
Jun. 30, 2015
USD ($)
|
Aug. 31, 2021
USD ($)
|
Aug. 31, 2021
ILS (₪)
|
Mar. 31, 2021
USD ($)
|
Mar. 31, 2022
USD ($)
|
Mar. 31, 2022
ILS (₪)
|
Dec. 31, 2022
USD ($)
shares
|
Dec. 31, 2022
ILS (₪)
|
Dec. 31, 2021
USD ($)
|
Jul. 31, 2019 |
May 31, 2017
shares
|
|
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||||
| Commitment, description | A.In March 2021, the IIA approved two new applications in relation to the Company’s cystic fibrosis product candidate for an aggregate budget of NIS 10,879 (approximately $3,286) and for the Company’s product candidate for Inflammatory Bowel Disease (“IBD”) and Primary Sclerosing Cholangitis for an aggregate revised budget of NIS 6,753 (approximately $2,118). | |||||||||||||||
| Aggregate budget | $ 3,286 | |||||||||||||||
| Aggregate revised budget | 2,118 | |||||||||||||||
| Percentage of total fund | 30.00% | 30.00% | ||||||||||||||
| Received amount of programs | $ 577 | ₪ 1,912 | ||||||||||||||
| Received amount | $ 395 | $ 150 | ||||||||||||||
| Aggregate budget | $ 1,778 | ₪ 5,737 | $ 4,094 | ₪ 13,004 | ||||||||||||
| Received amount (in Shares) | shares | 1,365,000 | |||||||||||||||
| Total approved grants | $ 8,403 | 28,683 | ||||||||||||||
| Total grants received | 6,957 | ₪ 23,634 | ||||||||||||||
| Total grants subject to royalties | 6,380 | |||||||||||||||
| Total contingent obligation | 6,557 | |||||||||||||||
| License agreement amount | $ 15 | $ 1,800 | ||||||||||||||
| License fees | $ 10 | 10 | ||||||||||||||
| Exit fee percentage | 1.00% | |||||||||||||||
| Warrant purchase shares (in Shares) | shares | 591,382 | |||||||||||||||
| Consideration received percentage | 1.00% | |||||||||||||||
| Paid an initial license fee | $ 25 | |||||||||||||||
| License maintenance fees | $ 250 | 250 | ||||||||||||||
| Development and commercialization | $ 4,700 | $ 2,350 | ||||||||||||||
| Aggregate amount | $ 32,100 | $ 148 | $ 175 | |||||||||||||
| Annual license fees,description | In return, the Company is required (i) to pay a license issue fee of $20 and annual license fees ranging from $15 to $25 (ii) make additional payments based upon the achievement of clinical and regulatory milestones up to an aggregate of $32,100 and (iii) make tiered royalty payments, in the low single digits based on future revenue. The consolidated financial statements include liabilities with respect to this agreement in the amount of $40 and $40 as of December 31, 2022 and 2021, respectively, recorded as other liabilities. | |||||||||||||||
| Receive fees | $ 439 | |||||||||||||||
| Installments amount | $ 50 | |||||||||||||||
| Percentage of income tax | 50.00% | |||||||||||||||
| Received fees | $ 1,411 | |||||||||||||||
| Collaboration agreement, description | The fees will be paid in instalments of $500 within 30 days of the Second Agreement Effective Date and three additional installments of $500, $200 and $211 upon completion of certain activities under the research plan. Unless terminated earlier, this agreement will remain in effect until (a) a period of eighteen (18) months thereafter or (b) completion of the project plan and submission and approval of the final report, whichever occurs sooner, unless otherwise extended. The consideration is recorded as a reduction of R&D expenses, net in the consolidated statements of operations according to the input model method on a cost-to-cost basis. The remainder of the consideration is recorded as other accounts payable in the consolidated balance sheets. As of December 31, 2022, the Company received consideration of $500 and recorded $287 in the consolidated statements of operations. | |||||||||||||||
| Minimum [Member] | ||||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||||
| Percentage of total fund | 30.00% | |||||||||||||||
| Royalties rate | 3.00% | 3.00% | ||||||||||||||
| Maximum [Member] | ||||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||||
| Percentage of total fund | 50.00% | 50.00% | ||||||||||||||
| Royalties rate | 3.50% | 3.50% | ||||||||||||||
| BiomX Israel [Member] | ||||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||||
| Received amount of programs | ₪ | ₪ 4,284 | |||||||||||||||
| Received amount | $ 1,347 | $ 439 | ||||||||||||||
| License agreement amount | $ 25 | |||||||||||||||
| Agreement amount | $ 100 | |||||||||||||||
| BiomX Israel [Member] | Minimum [Member] | ||||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||||
| Agreement amount | 150 | |||||||||||||||
| BiomX Israel [Member] | Maximum [Member] | ||||||||||||||||
| Commitments and Contingencies (Details) [Line Items] | ||||||||||||||||
| Agreement amount | $ 139 | |||||||||||||||